



**SDI Review Form 1.6**

Journal Name:	<b><u><a href="#">British Journal of Medicine and Medical Research</a></u></b>
Manuscript Number:	<b>2013_BJMMR_6435</b>
Title of the Manuscript:	<b>FACTORS THAT INFLUENCE COMPLIANCE WITH ANNUAL IVERMECTIN TREATMENT AND WILLINGNESS OF INDIVIDUALS TO CONTINUE WITH THE TREATMENT IN ABIA STATE, NIGERIA</b>
Type of the Article	

**General guideline for Peer Review process:**

This journal's peer review policy states that **NO** manuscript should be rejected only on the basis of '**lack of Novelty**', provided the manuscript is scientifically robust and technically sound.

To know the complete guideline for Peer Review process, reviewers are requested to visit this link:

(<http://www.sciencedomain.org/page.php?id=sdi-general-editorial-policy#Peer-Review-Guideline>)



**SDI Review Form 1.6**

**PART 1: Review Comments**

	<b>Reviewer's comment</b>	<b>Author's comment</b> <i>(if agreed with reviewer, correct the manuscript and highlight that part in the manuscript. It is mandatory that authors should write his/her feedback here)</i>
<b>Compulsory</b> REVISION comments	<p>The sample size of the questionnaire is not clear; we read that it is 558, but in Table 1 it reads N=487 for one set of responses and N=71 for the second column of responses. It may be a matter of wording, but the figures do not seem consistent.</p> <p>There are numerous grammatical, diction and syntax errors that suggest the need for a close English language review.</p>	
<b>Minor</b> REVISION comments	<p>Ivermectin, ivermectin, and Mectizan are used throughout and interchanged, without defining the relation, i.e., that ivermectin is the generic name for the brand name drug Mectizan, donated by Merck / MSD for use in APOC's activities. Ivermectin, as a generic name, is not capitalized.</p> <p>Line 103 - The abbreviation "CDD" is never defined.</p> <p>Line 46 - APOC's original target was a minimum – not maximum - 65% coverage rate.</p> <p>The paper's flow might be improved if the discussion section were further divided into a section on positive factors and a section of negative factors. As written, the data and narrative seem to merge into one another.</p> <p>Line 130 – the APOC goal is "elimination", not "eradication", of onchocerciasis.</p>	



**SDI Review Form 1.6**

	<p>Line 120 and various - "Onchocerciasis" should not be generally capitalized.</p> <p>Line 30 – readers may want to know when APOC was formed.</p>	
<b><u>Optional/General</u></b> comments	<p>The subject matter of issues that support or hamper ivermectin coverage rates is an important one that deserves more attention in the public health debate.</p>	

**Reviewer Details:**

Name:	<b>Ken Gustavsen</b>
Department, University & Country	<b>Merck and Co. Inc. in Whitehouse Station, New Jersey, USA</b>